Axa S.A. Buys 15,390 Shares of Turning Point Therapeutics, Inc. (NASDAQ:TPTX)

Axa S.A. boosted its holdings in shares of Turning Point Therapeutics, Inc. (NASDAQ:TPTX) by 18.9% in the 2nd quarter, Holdings Channel reports. The firm owned 96,896 shares of the company’s stock after buying an additional 15,390 shares during the period. Axa S.A.’s holdings in Turning Point Therapeutics were worth $7,560,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in TPTX. BlackRock Inc. lifted its stake in Turning Point Therapeutics by 21.3% during the second quarter. BlackRock Inc. now owns 3,855,203 shares of the company’s stock worth $300,782,000 after purchasing an additional 677,558 shares during the last quarter. Westfield Capital Management Co. LP lifted its stake in Turning Point Therapeutics by 119.8% during the second quarter. Westfield Capital Management Co. LP now owns 907,760 shares of the company’s stock worth $70,823,000 after purchasing an additional 494,755 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Turning Point Therapeutics by 36.2% during the second quarter. Alliancebernstein L.P. now owns 1,438,406 shares of the company’s stock worth $112,224,000 after purchasing an additional 382,520 shares during the last quarter. Cormorant Asset Management LP lifted its stake in Turning Point Therapeutics by 15.0% during the first quarter. Cormorant Asset Management LP now owns 2,750,000 shares of the company’s stock worth $260,122,000 after purchasing an additional 357,703 shares during the last quarter. Finally, Frontier Capital Management Co. LLC lifted its stake in Turning Point Therapeutics by 7,248.9% during the second quarter. Frontier Capital Management Co. LLC now owns 271,834 shares of the company’s stock worth $21,208,000 after purchasing an additional 268,135 shares during the last quarter. Hedge funds and other institutional investors own 92.32% of the company’s stock.

NASDAQ TPTX opened at $47.03 on Thursday. The company has a market capitalization of $2.32 billion, a price-to-earnings ratio of -14.21 and a beta of 1.00. Turning Point Therapeutics, Inc. has a twelve month low of $42.51 and a twelve month high of $141.30. The stock has a fifty day simple moving average of $69.65 and a 200 day simple moving average of $71.96.

Turning Point Therapeutics (NASDAQ:TPTX) last posted its quarterly earnings data on Monday, August 9th. The company reported ($1.14) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.20) by $0.06. The company had revenue of $5.16 million during the quarter. During the same period last year, the firm earned ($0.82) EPS. Sell-side analysts anticipate that Turning Point Therapeutics, Inc. will post -4.51 earnings per share for the current year.

In related news, EVP Annette North sold 10,000 shares of the stock in a transaction on Monday, August 30th. The stock was sold at an average price of $80.00, for a total value of $800,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 7.30% of the company’s stock.

Several brokerages have recently issued reports on TPTX. Stifel Nicolaus began coverage on shares of Turning Point Therapeutics in a report on Wednesday, September 29th. They set a “hold” rating and a $75.00 price target for the company. Wells Fargo & Company lowered their price target on shares of Turning Point Therapeutics from $160.00 to $120.00 and set an “overweight” rating for the company in a report on Thursday, October 7th. JMP Securities downgraded shares of Turning Point Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday. Zacks Investment Research downgraded shares of Turning Point Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, HC Wainwright lowered their price target on shares of Turning Point Therapeutics from $178.00 to $162.00 and set a “buy” rating for the company in a report on Tuesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $137.10.

Turning Point Therapeutics Company Profile

Turning Point Therapeutics, Inc is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor.

Recommended Story: How does the Beige Book influence monetary policy?

Want to see what other hedge funds are holding TPTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Turning Point Therapeutics, Inc. (NASDAQ:TPTX).

Institutional Ownership by Quarter for Turning Point Therapeutics (NASDAQ:TPTX)

Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.